Systemic analysis reveals clopidogrel's edge over aspirin in secondary prevention of coronary artery disease
Original framing: “[Correspondence] Clopidogrel versus aspirin for coronary artery disease” — The Lancet
The core argument rests on robust meta‑analytic data, randomized controlled trials, and systematic reviews that demonstrate clopidogrel's superior efficacy in secondary prevention. Methodological rigor and statistical significance are foregrounded, providing a strong scientific foundation for the claim.
The systemic advantage of clopidogrel over aspirin is grounded in solid scientific evidence, yet its full realization demands historical awareness, cross‑cultural equity, and future‑oriented modelling.
By weaving in Indigenous knowledge, marginalised perspectives, and a trickster critique of profit‑driven narratives, we uncover hidden barriers to implementation. Actionable pathways—pharmacogenomic integration, equitable access, dynamic guidelines, and inclusive advisory bodies—translate this multidimensional insight into concrete health system transformation.